Hiroki Hidejima
Directeur/Membre du Conseil chez METAREAL CORPORATION
Fortune : 1 M $ au 30/04/2024
Postes actifs de Hiroki Hidejima
Sociétés | Poste | Début | Fin |
---|---|---|---|
METAREAL CORPORATION | Directeur/Membre du Conseil | 01/04/2004 | - |
J & I YK | Directeur/Membre du Conseil | 01/02/2004 | - |
YES-fm KK | Comptroller/Controller/Auditor | 01/03/2005 | - |
C.H.C. SYSTEM Co., Ltd. | Directeur/Membre du Conseil | 01/05/2005 | - |
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Directeur/Membre du Conseil | 01/07/2010 | - |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Directeur/Membre du Conseil | 01/06/2014 | - |
THANN Natural KK | Directeur/Membre du Conseil | 01/06/2012 | - |
Development Association For Youthleaders | Directeur/Membre du Conseil | 01/03/2004 | - |
Historique de carrière de Hiroki Hidejima
Formation de Hiroki Hidejima
Kobe University Graduate School of Business Administration | Undergraduate Degree |
Statistiques
Internationale
Japon | 9 |
Allemagne | 2 |
Opérationnelle
Director/Board Member | 7 |
Undergraduate Degree | 1 |
Comptroller/Controller/Auditor | 1 |
Sectorielle
Commercial Services | 2 |
Technology Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
METAREAL CORPORATION | Technology Services |
Entreprise privées | 7 |
---|---|
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Commercial Services |
C.H.C. SYSTEM Co., Ltd. | |
THANN Natural KK | |
J & I YK | |
YES-fm KK | |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Health Technology |
Development Association For Youthleaders |
- Bourse
- Insiders
- Hiroki Hidejima
- Expérience